Nevertheless, considering that VEGF showed a significant decrease after systemic treatment with methotrexate or azathioprine in patients with AD [15], this molecule could be regarded as a potentially important mediator in the pathogenesis of AD, a practicable biomarker correlating with severity and therapeutic response in patients with AD. The gene discussed is VEGFA; the disease is Alzheimer disease.